Literature DB >> 9443621

Evaluation of damaged small intestine of mouse following methotrexate administration.

M Nakamaru1, Y Masubuchi, S Narimatsu, S Awazu, T Horie.   

Abstract

PURPOSE: Methotrexate (MTX) treatment causes damage to the small intestine, resulting in malabsorption and diarrhea. The active and passive transport capacities of the small intestine are decreased by the treatment. The purpose of this study was to evaluate the damage to the small intestine of mice caused by MTX administration by examining the permeability of the paracellular pathway of the small intestinal epithelium.
METHODS: MTX was administered orally to male ddY mice once daily for 1-6 days. The permeability of the small intestine to the nonabsorbable markers phenol red (PR) and fluorescein isothiocyanate (FITC) dextrans was examined using everted segments of the intestine.
RESULTS: PR and FITC dextran permeation through the small intestine increased significantly in parallel with changes in body weight of the mice, wet weight of the small intestine and chemical composition of the small intestinal epithelium.
CONCLUSIONS: In addition to changes in permeation through the transcellular pathway reported previously, this study revealed that MTX treatment disorders the paracellular barrier function of the small intestinal epithelium, resulting in increased permeation of nonabsorbable markers via the paracellular pathway of the small intestinal mucosa. The present approach to the examination of the barrier function of the intestinal epithelium could be of great use in evaluating the damage to the small intestine and malabsorption.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443621     DOI: 10.1007/s002800050714

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  Gut in diseases: physiological elements and their clinical significance.

Authors:  Lian-An Ding; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

2.  Variability of oral bioavailability for low dose methotrexate in rats.

Authors:  T Kuroda; K Namba; T Torimaru; S Yamamoto; M Akahori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 3.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

4.  Evaluation of mucosal damage and recovery in the gastrointestinal tract of rats by a penetration enhancer.

Authors:  Yogeeta Narkar; Ronald Burnette; Reiner Bleher; Ralph Albrecht; Angki Kandela; Joseph R Robinson
Journal:  Pharm Res       Date:  2007-12-27       Impact factor: 4.200

5.  Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis.

Authors:  B A Carneiro-Filho; I P F Lima; D H Araujo; M C Cavalcante; G H P Carvalho; G A C Brito; V Lima; S M N Monteiro; F N Santos; R A Ribeiro; A A M Lima
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

6.  Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.

Authors:  Matthew Siegel; Pavel Strnad; R Edward Watts; Kihang Choi; Bana Jabri; M Bishr Omary; Chaitan Khosla
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

7.  Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice.

Authors:  Seong-Kwan Kim; Soo-Jeong Shin; Yohan Yoo; Na-Hyun Kim; Dong-Soon Kim; Dan Zhang; Jin-A Park; Hee Yi; Jin-Suk Kim; Ho-Chul Shin
Journal:  Exp Ther Med       Date:  2015-01-22       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.